LLYEli Lilly and CompanyRunning, no new patients
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Breast Neoplasm · Neoplasm Metastasis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 368 (final count)
- Started
- Mar 11, 2022
- Main results expected
- Feb 8, 2024
- Fully finished
- Dec 2027
- Results posted
- Feb 27, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05169567 · record last updated 2026-10-06 · checked 2026-11-09 15:42 UTC